INTRODUCTION
The treatment of bipolar depression (BD) has not received as much attention as the treatment of mania or unipolar depression. 1, 2 So far, no single antidepressant has proved efficacy in the treatment of BD in at least two controlled clinical trials performed. 3 Moreover, there is always a concern that antidepressants may cause a manic switch in bipolar patients, especially the tricyclic drugs. 4 On the other hand, mood stabilizers (among them lithium, carbamazepine and valproate)
seem to be more effective in mania than in depression 5 and they are associated to a significant worsening of cognitive performance. 6 Lamotrigine is an anticonvulsant that has been employed in the treatment of bipolar disorder (BPD). Many clinical trials indicate that, although lamotrigine is not effective in acute mania nor in the prevention of manic episodes, it is helpful in the acute phase of BD and in the prophylaxis of future depressive episodes. 7, 8 A major benefit with the use of lamotrigine in BD is that, although it has an antidepressant activity, it is associated to a low rate of manic switch or hypomania, even during monotherapy. In the study developed by Calabrese et al., 5 only 5.4% of depressed bipolar patients taking lamotrigine had a switch, as compared to the 4.6% who were given placebo, a non-significant difference. In the 52-week, open-label study of lamotrigine as maintainance treatment of depression in bipolar patients, carried out by McElroy et al., 9 patients had less manic or hypomanic episodes than the year before. Another important characteristic of lamotrigine is that it seems not to affect cognition. 6, 10 On the other hand, this drug has been associated with an increased risk of rashes, which are in general benign, but sometimes may be life-threatening.
CASE REPORT
The patient is natural from Rio de Janeiro, where he lives; he is divorced, graduated and works as a civil servant in one of the most important public institutions in the country. In November 2000, at the age of 35, he got a leave to carry out a doctorate degree. Up to that moment, he had 3 already presented several depressive and hypomanic episodes, the first one at the age of 14, but he had never been admitted to a psychiatric institution. At that time, the diagnosis was BPD type II.
Between successfully. Sometimes he did not go to work or arrived late, but once depression was over, he returned to his normal rhythm of work. In November 2004, he was then 39, the depressive episodes became more frequent, and the patient decided to take medication again. However, he did not admit taking lithium or divalproate, justifying that they impaired his intellectual performance, which was essential in his professional activities.
Monotherapy with lamotrigine 12.5 mg/day in alternated days was prescribed. After two days, the dosage was 25 mg/day and the patient had a significant ammelioration of depressive symptoms and no side effect at all, and he became quite confident on the treatment. In the following month, December, the dosage was at 50 mg/day and after 10 days, the patient entered what seemed to be a manic episode. He showed irritability, became arrogant and suspicious -though not delusional -started to spend much money and had his sexual drive substantially increased.
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Medication was discontinued and about 15 days later all symptoms remitted. In March 2005 he was not taking any psychotropic drug and presented a new depressive episode.
DISCUSSION
In BPD II, the management of depressive episodes is of paramount importance, as they are more frequent, long and severe than the episodes of hypomania. 3 Moreover, in this mental disorder, the risk of suicide is higher than in unipolar depression or in BPD I. 2 According to some therapeutic guidelines designed by international specialists, in the less severe cases of BD, lithium in monotherapy must be used. In the most severe cases, the first alternative must be the association of a mood stabilizer with an antidepressant. The most indicated mood stabilizers are lithium and lamotrigine, but valproate and carbamazepine may also be used.
Among antidepressants, the preference is for selective serotonin reuptake inhibitors, bupropion and venlafaxine, which would not induce a switch into mania as frequent as others. The case reported here, lamotrigine, corresponding to our expectations, improved the depressive symptoms with no side affects as to cognition. Surprisingly, however, its prescription was associated with a manic switch. It is not possible to assure that lamotrigine was the cause of this event, provided that it can occur even with placebo. Besides, there may have been a coincidence: a manic episode could have taken place even if the patient had not taken any medication, it could have been only part of the natural course of his illness. But we consider that, at least in this patient -and maybe in other cases of bipolarity -it may be safer to avoid the prescription of lamotrigine alone, using it preferably in association with another mood stabilizer, as lithium, valproate or carbamazepine.
